Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
GlobeNewswire, Inc.
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedented two-year data from the trial including a 75% Objective Response Rate with 25% of patients...
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
GlobeNewswire, Inc.
Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker with pipeline-in-a-product...
Omnidocs strengthens market position with acquisition of WoodWing, backed by Main Capital Partners
EIN Presswire
COPENHAGEN, DENMARK, October 19, 2026 /EINPresswire.com/ -- Omnidocs Group (‘Omnidocs’) and WoodWing today announce their strategic combination, bringing together complementary software solutions across document generation and automation,...
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
GlobeNewswire, Inc.
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma’s expertise in...
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
GlobeNewswire, Inc.
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M...
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook
EIN Presswire
The Business Research Company's Small Molecule Active Pharmaceutical Ingredient Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 13, 2026 /EINPresswire.com/ -- "The small...
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
GlobeNewswire, Inc.
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial guidance for the full year...
University Hospitals Expands ESO Service Arrangement to Deliver Prehospital Intelligence Across Northern Ohio
GlobeNewswire, Inc.
CLEVELAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- University Hospitals (UH), the Cleveland-based health system serving patients across northern Ohio, has expanded its partnership with ESO, a leading data services and software provider for fire...
Kubbco releases new controversial new breast-health film
EIN Presswire
A question you shouldn’t ask. A conversation we can’t avoid.
Disposable Medical Device Market to Reach USD 144.85 Billion by 2030, Growing at a CAGR of 4.9% – MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL , Oct. 05, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global disposable medical devices market to grow from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, at a CAGR of 4.9% during the forecast period....
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
GlobeNewswire, Inc.
- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the placebo arm (p=0.0248); HS...
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
GlobeNewswire, Inc.
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2...
King’s College Hospital London - Dubai Breaks Ground on Major Hospital Expansion
EIN Presswire
Phase 2 expansion will increase the hospital to 200 beds and further develop specialist and complex care services in Dubai DUBAI, UNITED ARAB EMIRATES, September 30, 2026 /EINPresswire.com/ -- Phase 2 expansion will increase the hospital to 200...
Pet Anxiety Awareness Day Launches in Europe October 12 supported by Orion Pharma Animal Health
EIN Presswire
New veterinary-focused initiative brings a decade of U.S. education on fear, anxiety, and stress (FAS) in companion animals to European veterinary clinics TAMPA, FL, UNITED STATES, September 30, 2026 /EINPresswire.com/ -- Pet Anxiety Awareness...
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
GlobeNewswire, Inc.
Press release – No. 18 / 2026 Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology Treatment with petrelintide was...
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
GlobeNewswire, Inc.
- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR),...
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
GlobeNewswire, Inc.
HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties Bagsværd, Denmark, 29...
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
GlobeNewswire, Inc.
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the new management, given...
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
GlobeNewswire, Inc.
Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078),...
Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors
GlobeNewswire, Inc.
London, September 28, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Eva Ehrnrooth, MD, PhD, as Executive Head of Clinical Development and Chau Khuong to its Board of Directors.
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.